Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E1308: Induction Chemo and Cetuximab with Reduced-Dose IMRT in HPV+ OPSCC
NCT01084083Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Aug 2010
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Eastern Cooperative Oncology Group. Started Aug 2010; status: completed.
02
Drugs
KL-140
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT01084083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01084083.